Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.

Kawashima R, Abei M, Fukuda K, Nakamura K, Murata T, Wakayama M, Seo E, Hasegawa N, Mizuguchi H, Obata Y, Hyodo I, Hamada H, Yokoyama KK.

Int J Cancer. 2011 Sep 1;129(5):1244-53. doi: 10.1002/ijc.25758. Epub 2011 Jan 6.

2.

Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors.

Tanaka T, Huang J, Hirai S, Kuroki M, Kuroki M, Watanabe N, Tomihara K, Kato K, Hamada H.

Clin Cancer Res. 2006 Jun 15;12(12):3803-13.

3.

Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors.

Heideman DA, Snijders PJ, Craanen ME, Bloemena E, Meijer CJ, Meuwissen SG, van Beusechem VW, Pinedo HM, Curiel DT, Haisma HJ, Gerritsen WR.

Cancer Gene Ther. 2001 May;8(5):342-51.

4.

Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration.

Seo E, Abei M, Wakayama M, Fukuda K, Ugai H, Murata T, Todoroki T, Matsuzaki Y, Tanaka N, Hamada H, Yokoyama KK.

Cancer Res. 2005 Jan 15;65(2):546-52.

5.

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

Haisma HJ, Pinedo HM, Rijswijk A, der Meulen-Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR, Curiel DT.

Gene Ther. 1999 Aug;6(8):1469-74.

6.

Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy.

Takahashi S, Kato K, Nakamura K, Nakano R, Kubota K, Hamada H.

Cancer Sci. 2011 Apr;102(4):808-14. doi: 10.1111/j.1349-7006.2011.01855.x. Epub 2011 Feb 25.

7.

Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.

Zhang Y, Qin X, Zhang Y, Zhao L, Wang Y, Liu X, Yao L.

J Cancer Res Clin Oncol. 2008 Feb;134(2):219-26. Epub 2007 Jul 14.

PMID:
17632733
8.

Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.

Kadota K, Huang CL, Liu D, Yokomise H, Haba R, Wada H.

Int J Oncol. 2011 Feb;38(2):355-63. doi: 10.3892/ijo.2010.880. Epub 2010 Dec 20.

PMID:
21174056
9.

Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2010 Dec;20(9):1440-7.

10.

Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid.

Volpers C, Thirion C, Biermann V, Hussmann S, Kewes H, Dunant P, von der Mark H, Herrmann A, Kochanek S, Lochmüller H.

J Virol. 2003 Feb;77(3):2093-104.

11.

Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism.

Heideman DA, van Beusechem VW, Offerhaus GJ, Wickham TJ, Roelvink PW, Craanen ME, Pinedo HM, Meijer CJ, Gerritsen WR.

Hum Gene Ther. 2002 Sep 20;13(14):1677-85.

PMID:
12396621
12.

Exploration of target molecules for prostate cancer gene therapy.

Suzuki K, Nakamura K, Kato K, Hamada H, Tsukamoto T.

Prostate. 2007 Aug 1;67(11):1163-73.

PMID:
17516570
13.

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675. Epub 2010 Jan 6.

14.

[Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].

Guo MG, Jiang MH, Yang Q, Li YM, Cui ZF, Li LF, Wu MC, Qian QJ.

Zhonghua Yi Xue Za Zhi. 2004 Jul 17;84(14):1147-51. Chinese.

PMID:
15387973
15.

Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors.

Oonuma M, Sunamura M, Motoi F, Fukuyama S, Shimamura H, Yamauchi J, Shibuya K, Egawa S, Hamada H, Takeda K, Matsuno S.

Int J Cancer. 2002 Nov 1;102(1):51-9.

16.

C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.

Elliott MJ, Stilwell A, Dong YB, Yang HL, Wong SL, Wrightson WR, Martin RC, McMasters KM.

Cancer Gene Ther. 2002 May;9(5):453-63.

17.

EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.

Matsuda T, Takeuchi H, Matsuda S, Hiraiwa K, Miyasho T, Okamoto M, Kawasako K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Omori T, Kitagawa Y.

Ann Surg Oncol. 2014 Jun;21 Suppl 3:S356-64. doi: 10.1245/s10434-014-3579-8. Epub 2014 Feb 25.

PMID:
24566863
18.

An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.

Liao MY, Lai JK, Kuo MY, Lu RM, Lin CW, Cheng PC, Liang KH, Wu HC.

Oncotarget. 2015 Sep 22;6(28):24947-68. doi: 10.18632/oncotarget.4453.

19.

Chemo-radio-gene therapy for colorectal cancer cells using Escherichia coli uracil phosphoribosyltransferase gene.

Koyama F, Fujii H, Mukogawa T, Ueno M, Hamada H, Ishikawa H, Doi S, Nakao T, Matsumoto H, Shimatani H, Takeuchi T, Nakajima Y.

Anticancer Res. 2003 Mar-Apr;23(2B):1343-8.

PMID:
12820392
20.

Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.

Akbulut H, Tang Y, Maynard J, Zhang L, Pizzorno G, Deisseroth A.

Clin Cancer Res. 2004 Nov 15;10(22):7738-46.

Supplemental Content

Support Center